Q&A with Schenk AccuRate's Chad Lorensen - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Schenk AccuRate's Chad Lorensen
Lorensen discusses client demands and industry trends.

Pharmaceutical Technology
Volume 34, Issue 5, pp. 86

Q & A with
Chad Lorensen, pharmaceutical industry business-development manager of Schenck AccuRate



PharmTech:
What is the biggest industry challenge you're now facing?

Lorensen
The development of continuous manufacturing processes. We are monitoring, helping where we can, and working with companies in the pharmaceutical industry who are studying continuous manufacturing processes for solid dosage products. Our core products have the strengths that provide value for this type of manufacturing process.

PharmTech:
How do you stay abreast of new developments in the industry?

Lorensen
Schenck stays abreast of the latest industry developments through regular communication with our customers, developing strong working relationships with other pharmaceutical-industry equipment manufacturers, and by participating in research consortiums at various universities. Further information is gathered by reviewing various pharmaceutical periodicals and attending trade show exhibitions. In addition, Schenck is a global company, and each of its offices can share ideas with other Schenck locations throughout the world.

PharmTech:
Do you see a new industry trend emerging?

Lorensen
We are looking forward to the pharmaceutical industry's acceptance of continuous mixing, granulation, and hot-melt extrusion.

PharmTech:
What is the most common demand your clients are currently making of you?

Lorensen
The most common request is to provide equipment to customers' sites for trials and experiments made in conjunction with other types of continuous processing equipment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here